Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2015

01-01-2015 | Clinical Study

Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology

Authors: Tae-Young Jung, Ji Yeoun Lee, Dong-Seok Kim, Hyeon Jin Park, Chae-Yong Kim, Young-Shin Ra, Mee-Jeong Lee, Seong-Ho Kim, Hee-Jo Baek, Il Han Kim, Kyung Duk Park, Seung-Ki Kim

Published in: Journal of Neuro-Oncology | Issue 2/2015

Login to get access

Abstract

We analyzed the prognostic factors of Korean pediatric patients with supratentorial high-grade glioma (HGG). Between 1997 and 2011, 62 patients with 34 glioblastomas and 28 anaplastic gliomas were surgically operated at nine institutions. The male-to-female ratio was 33 to 29 and the median age was 12 years (range 1–18). The prognostic significance of tumor location, extent of removal, pathologic grade, treatment method, and pattern of recurrence was analyzed. The median progression-free survival (PFS) and overall survival (OS) were 9.3 (±0.8) and 17.8 (±1.9) months, respectively. Glioblastoma and anaplastic glioma showed OSs of 15.9 (±1.3) and 19.6 (±2.4) months, respectively. Based on the univariate analysis, gross total removal (GTR) and initial combined chemoradiotherapy improved PFS (p = 0.012 and p = 0.003) and OS (p = 0.030 and p = 0.013), respectively. Cerebrospinal fluid (CSF) dissemination showed poor OS (p = 0.001). Based on the multivariate analysis, GTR and initial combined chemoradiotherapy resulted in an improved PFS [(hazard ratio 0.360; 95 % CI 0.177–0.733; p = 0.005) and (hazard ratio 0.458; 95 % CI 0.230–0.911; p = 0.026), respectively]. GTR, initial combined chemoradiotherapy, and no CSF seeding resulted in an improved OS [(hazard ratio 0.417; 95 % CI 0.201–0.861; p = 0.018), (hazard ratio 0.406; 95 % CI 0.206–0.800; p = 0.009), and (hazard ratio 0.288; 95 % CI 0.148–0.563; p = 0.000), respectively]. No significant difference in PFS and OS was observed between glioblastoma and anaplastic glioma. CSF dissemination was observed in 22 patients (35.5 %) during total follow-up. Pediatric anaplastic glioma showed poor survival, similarly to glioblastoma. GTR and initial combined chemoradiotherapy were associated with improved survival.
Literature
1.
2.
go back to reference Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, Kim IH, Ahn HS, Park SH, Kim SK (2010) Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 6:145–149PubMedCrossRef Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, Kim IH, Ahn HS, Park SH, Kim SK (2010) Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 6:145–149PubMedCrossRef
3.
go back to reference Finlay JL, Wisoff JH (1999) The impact of extent of resection in the management of malignant gliomas of childhood. Child’s Nerv Syst 15:786–788CrossRef Finlay JL, Wisoff JH (1999) The impact of extent of resection in the management of malignant gliomas of childhood. Child’s Nerv Syst 15:786–788CrossRef
4.
go back to reference Campbell JW, Pollack IF, Martinez AJ, Shultz B (1996) High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 38:258–264PubMedCrossRef Campbell JW, Pollack IF, Martinez AJ, Shultz B (1996) High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 38:258–264PubMedCrossRef
5.
go back to reference Halperin EC (1992) Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas. J Neurooncol 14:255–262PubMed Halperin EC (1992) Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas. J Neurooncol 14:255–262PubMed
6.
go back to reference Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M et al (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Children’s Cancer Group. J Clin Oncol 13:112–123PubMed Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M et al (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Children’s Cancer Group. J Clin Oncol 13:112–123PubMed
7.
go back to reference Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. a report from the Children’s Cancer Study Group. J Neurooncol 7:165–177PubMedCrossRef Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. a report from the Children’s Cancer Study Group. J Neurooncol 7:165–177PubMedCrossRef
9.
go back to reference Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866–875 discussion 875PubMedCrossRef Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866–875 discussion 875PubMedCrossRef
11.
go back to reference Awad I, Bay JW, Rogers L (1986) Leptomeningeal metastasis from supratentorial malignant gliomas. Neurosurgery 19:247–251PubMedCrossRef Awad I, Bay JW, Rogers L (1986) Leptomeningeal metastasis from supratentorial malignant gliomas. Neurosurgery 19:247–251PubMedCrossRef
12.
go back to reference Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro-oncology 13:317–323. doi:10.1093/neuonc/noq191 PubMedCentralPubMedCrossRef Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro-oncology 13:317–323. doi:10.​1093/​neuonc/​noq191 PubMedCentralPubMedCrossRef
13.
go back to reference Heideman RL, Kuttesch J Jr, Gajjar AJ, Walter AW, Jenkins JJ, Li Y, Sanford RA, Kun LE (1997) Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer 80:497–504PubMedCrossRef Heideman RL, Kuttesch J Jr, Gajjar AJ, Walter AW, Jenkins JJ, Li Y, Sanford RA, Kun LE (1997) Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer 80:497–504PubMedCrossRef
14.
go back to reference Reifenberger G KJ, Burger P, Louis DN, Collins VP (2000) Astrocytic and oligodendroglioma. In: Kleihues P, Cavenee WK (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system, Lyon, France, IARC Press, p 56–67 Reifenberger G KJ, Burger P, Louis DN, Collins VP (2000) Astrocytic and oligodendroglioma. In: Kleihues P, Cavenee WK (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system, Lyon, France, IARC Press, p 56–67
15.
go back to reference Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987–996PubMedCrossRef Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987–996PubMedCrossRef
17.
go back to reference Ilveskoski I, Saarinen UM, Perkkio M, Salmi TT, Lanning M, Makipernaa A, Sankila R, Pihko H (1996) Chemotherapy with the “8 in 1” protocol for malignant brain tumors in children: a population-based study in Finland. Pediatr Hematol Oncol 13:69–80PubMedCrossRef Ilveskoski I, Saarinen UM, Perkkio M, Salmi TT, Lanning M, Makipernaa A, Sankila R, Pihko H (1996) Chemotherapy with the “8 in 1” protocol for malignant brain tumors in children: a population-based study in Finland. Pediatr Hematol Oncol 13:69–80PubMedCrossRef
19.
go back to reference Duffner PK, Cohen ME, Myers MH, Heise HW (1986) Survival of children with brain tumors: SEER Program, 1973-1980. Neurology 36:597–601PubMedCrossRef Duffner PK, Cohen ME, Myers MH, Heise HW (1986) Survival of children with brain tumors: SEER Program, 1973-1980. Neurology 36:597–601PubMedCrossRef
20.
go back to reference Jung TY, Kim CY, Kim DS, Ra YS, Kim SH, Baek HJ, Choi HS, Kim IA (2012) Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study. Child’s Nerv Syst 28:1033–1039. doi:10.1007/s00381-012-1786-9 CrossRef Jung TY, Kim CY, Kim DS, Ra YS, Kim SH, Baek HJ, Choi HS, Kim IA (2012) Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study. Child’s Nerv Syst 28:1033–1039. doi:10.​1007/​s00381-012-1786-9 CrossRef
21.
go back to reference Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children’s Cancer Group 945 cohort. J Neurosurg 105:418–424. doi:10.3171/ped.2006.105.5.418 PubMedCrossRef Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children’s Cancer Group 945 cohort. J Neurosurg 105:418–424. doi:10.​3171/​ped.​2006.​105.​5.​418 PubMedCrossRef
22.
go back to reference Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812. doi:10.1126/science.1164382 PubMedCentralPubMedCrossRef Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812. doi:10.​1126/​science.​1164382 PubMedCentralPubMedCrossRef
23.
go back to reference Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, Sposto R (2002) Expression of p53 and prognosis in children with malignant gliomas. New Engl J Med 346:420–427. doi:10.1056/NEJMoa012224 PubMedCrossRef Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, Sposto R (2002) Expression of p53 and prognosis in children with malignant gliomas. New Engl J Med 346:420–427. doi:10.​1056/​NEJMoa012224 PubMedCrossRef
24.
go back to reference Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474. doi:10.1007/s00401-009-0561-9 PubMedCrossRef Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474. doi:10.​1007/​s00401-009-0561-9 PubMedCrossRef
25.
26.
go back to reference Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, Finlay JL (1998) Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 89:52–59. doi:10.3171/jns.1998.89.1.0052 PubMedCrossRef Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, Finlay JL (1998) Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 89:52–59. doi:10.​3171/​jns.​1998.​89.​1.​0052 PubMedCrossRef
27.
go back to reference Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24:3431–3437. doi:10.1200/JCO.2006.05.7265 PubMedCrossRef Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24:3431–3437. doi:10.​1200/​JCO.​2006.​05.​7265 PubMedCrossRef
28.
go back to reference Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403–407. doi:10.1002/pbc.20803 PubMedCrossRef Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403–407. doi:10.​1002/​pbc.​20803 PubMedCrossRef
30.
go back to reference Barone G, Maurizi P, Tamburrini G, Riccardi R (2006) Role of temozolomide in pediatric brain tumors. Child’s Nerv Syst 22:652–661CrossRef Barone G, Maurizi P, Tamburrini G, Riccardi R (2006) Role of temozolomide in pediatric brain tumors. Child’s Nerv Syst 22:652–661CrossRef
31.
go back to reference Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20:4684–4691PubMedCrossRef Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20:4684–4691PubMedCrossRef
32.
go back to reference Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramuzza D, Ravagnani F, Fossati-Bellani F (2005) Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro-oncology 7:41–48. doi:10.1215/S1152851704000304 PubMedCentralPubMedCrossRef Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramuzza D, Ravagnani F, Fossati-Bellani F (2005) Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro-oncology 7:41–48. doi:10.​1215/​S115285170400030​4 PubMedCentralPubMedCrossRef
33.
go back to reference Wolff JE, Gnekow AK, Kortmann RD, Pietsch T, Urban C, Graf N, Kuhl J (2002) Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 94:264–271PubMedCrossRef Wolff JE, Gnekow AK, Kortmann RD, Pietsch T, Urban C, Graf N, Kuhl J (2002) Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 94:264–271PubMedCrossRef
34.
go back to reference Arita N, Taneda M, Hayakawa T (1994) Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126:84–92CrossRef Arita N, Taneda M, Hayakawa T (1994) Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126:84–92CrossRef
36.
go back to reference Grabb PA, Albright AL, Pang D (1992) Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children. Neurosurgery 30:64–71PubMedCrossRef Grabb PA, Albright AL, Pang D (1992) Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children. Neurosurgery 30:64–71PubMedCrossRef
Metadata
Title
Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology
Authors
Tae-Young Jung
Ji Yeoun Lee
Dong-Seok Kim
Hyeon Jin Park
Chae-Yong Kim
Young-Shin Ra
Mee-Jeong Lee
Seong-Ho Kim
Hee-Jo Baek
Il Han Kim
Kyung Duk Park
Seung-Ki Kim
Publication date
01-01-2015
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1653-5

Other articles of this Issue 2/2015

Journal of Neuro-Oncology 2/2015 Go to the issue